A Phase 1 Study to Evaluate the Safety, Proliferation and Persistence of GEN-011, an Autologous Adoptive Cell Therapy Targeting Neoantigens in Solid Tumors
TiTAN-1 is a first-in-human study of GEN-011, an experimental treatment being evaluated in adult patients with advanced cancer. GEN-011 is a T cell therapy made specific to each patient, using the patient's own circulating immune cells. First, Genocea confirms which cancer proteins are recognized already by each patient's T cells using ATLAS™. Then, immune cells that recognize these cancer proteins are multiplied many times (a process called PLANET™) to create a personalized GEN-011 cell therapy, which is given back to the patient in one or more intravenous (IV) infusions.
-to evaluate the safety and toxicities of GEN-011 given in 2 dosing regimens
-to determine the proliferation and persistence of GEN-011 cells in patients using antigen-specific T cell responses
-to assess clinical response per RECIST and iRECIST criteria, including best response, duration of response (DoR), progression-free survival (PFS), and survival for those who do not progress up to 2 years post initial dose of GEN-011.
-to assess immune cell phenotypes, T cell receptor (TCR) beta chain sequences, epitope spreading, and residual or new mutations in residual or recurrent tumor.
-to assess immune cell infiltration of the tumor including quantitation, phenotype and proximity to tumor cells.
Diagnosis of one of the following solid tumors: cutaneous melanoma, non-small cell lung cancer (NSCLC), squamous cell carcinoma of the head and neck (SCCHN), urothelial carcinoma (UC), renal cell carcinoma (RCC), small cell lung cancer (SCLC), cutaneous squamous cell carcinoma (CSCC), anal squamous cell carcinoma (ASCC), merkel cell carcinoma (MCC).
Received, been intolerant of, or been ineligible to receive standard of care treatment regimen.
Measurable disease per RECIST criteria
Life expectancy > 6 months and ECOG status 0 or 1
Capacity to tolerate lymphodepletion (SHD group only) and IL-2 therapy
Tumor tissue available
Willing to use contraceptives for 90 days after receiving GEN-011, and not currently pregnant.
Adequate blood, liver, kidney, and lung function
Sufficient stimulatory neoantigens identified in ATLAS
Please call 1-888-663-3488 for support from a Moffitt representative. New Patients and Healthcare Professionals can submit an online form by selecting the appropriate buttonbelow. Existing patients can call 1-888-663-3488. Click here for a current list of insurances accepted at Moffitt.
NEW PATIENTS To request a new patient appointment, please fill out the online form or call 1-888-663-3488.
REFERRING PHYSICIANS Providers and medical staff can refer patients by submitting our online referral form.
Moffit now offers Virtual Visits for patients. If you are eligible for a virtual appointment, our scheduling team will discuss this option further with you.
Moffitt Cancer Center is committed to the health and safety of our patients and their families. For more information on how we’re protecting our new and existing patients, visit our COVID-19 Info Hub